XAIR News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

XA

Volume

14.61K

Next Earnings

November 9th

Loading chart

XA

XAIRBeyond Air, Inc. Common Stock

XAIR

Pay with—

Available Balance0.00

XA

Mkt Cap

$2.2M

Volume

14.61K

Next Earnings

November 9th

Chart Financials Earnings News About Insider Filings

Beyond Air Enters Definitive Agreement to Sell Its NeuroNOS Stake to UNIVO Pharmaceutical Industries in Exchange for Equity and Milestone PaymentsBeyond Air has agreed to sell its 58% stake in NeuroNOS to UNIVO Pharmaceutical Industries in exchange for 19.99% equity stake in UNIVO and up to $32.5 million in development and commercial milestone payments. The transaction allows Beyond Air to focus on its core LungFit business while NeuroNOS gains dedicated resources to advance its neurological disorder and brain cancer treatment pipeline.GlobeNewswire Inc. · Aug 25, 2026

Beyond Air (XAIR) Q4 2026 Earnings Call TranscriptBeyond Air reported fiscal 2026 revenue of $7.7 million, up 107% year-over-year, with a 90% customer renewal rate. The company is focusing resources on its LungFit PH nitric oxide delivery system and expects FDA approval of its second-generation device in late 2026. Management projects 2027 revenue of $16-18 million (110%+ growth) assuming Gen 2 launch, with expanded market access through three major GPO agreements covering ~7,000 hospitals. The company reduced net cash burn by 56% and achieved gross profit of $300,000 in fiscal 2026.The Motley Fool · Jun 27, 2026

Beyond Air, Inc. Urges Stockholders to Vote “FOR” All Proposals Ahead of the Upcoming Special MeetingBeyond Air (XAIR) is urging stockholders to vote in favor of a reverse stock split (1-for-2 to 1-for-20 ratio) at a June 18, 2026 special meeting to maintain its Nasdaq listing. The company received a delisting notice from Nasdaq on April 7, 2026, due to its stock price falling below the $1.00 minimum bid requirement for 30 consecutive business days. The reverse split is necessary to increase the per-share price and avoid delisting, which would impact capital access and investor eligibility.GlobeNewswire Inc. · Jun 10, 2026

Beyond Cancer Reports Updated Survival and Safety Data from Phase 1 UNO Trial Presented at AACR 2026Beyond Cancer, Ltd. presented updated Phase 1 trial data showing six of ten heavily pre-treated cancer patients remain alive 22-40 months after a single UNO (ultra-high concentration nitric oxide) injection. Two triple negative breast cancer patients showed no evidence of disease. The company also received a U.S. patent allowance for its proprietary gas delivery technology. Safety profile was generally favorable with mostly Grade 1-2 adverse events.GlobeNewswire Inc. · Apr 20, 2026

Beyond Air to Participate in the 38th Annual Roth Conference in MarchBeyond Air, Inc. (NASDAQ: XAIR) announced that Chairman & CEO Steve Lisi will participate in the 38th Annual Roth Conference on March 23, 2026, in Laguna Niguel, CA. The company will present via fireside chat and offer one-on-one meetings with investors. Beyond Air is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide therapies for respiratory illnesses, neurological disorders, and solid tumors.GlobeNewswire Inc. · Mar 11, 2026

Beyond Air® Comments on Landmark Independent Review Article Highlighting the Antimicrobial Effects of High-Dose Inhaled Nitric Oxide and its Therapeutic Potential for Treating Respiratory InfectionsBeyond Air commented on the publication of an independent peer-reviewed article in Intensive Care Medicine Experimental that highlights the therapeutic potential of high-dose inhaled nitric oxide (iNO) for treating respiratory infections. The article synthesized data from 27 studies showing high-dose iNO's multimodal antimicrobial activity and potential applications in hospital-acquired pneumonia, COVID-19, bronchiolitis, and nontuberculous mycobacteria. Beyond Air's CEO stated the publication validates the company's clinical programs and could accelerate development of high-dose iNO as a transformative treatment.GlobeNewswire Inc. · Feb 20, 2026

Beyond Air Deals Autism-Focused NeuroNOS To XTL For Equity, Future PaymentsBeyond Air Inc. (NASDAQ:XAIR) has agreed to sell 85% of its subsidiary NeuroNOS Ltd. to XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) in exchange for 19.9% equity stake in XTL, $1 million cash, and up to $32.5 million in milestone-based payments. NeuroNOS, which focuses on autism therapeutics and holds FDA Orphan Drug Designations, will become XTL's flagship platform. Beyond Air shares surged 163.70% on the announcement.Benzinga · Jan 13, 2026

XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific LeadershipXTL Biopharmaceuticals announced a binding agreement to acquire 85% of NeuroNOS Ltd., a subsidiary of Beyond Air, Inc., positioning itself as a major player in autism therapeutics. The acquisition includes two Nobel Laureates in Chemistry and autism researcher Prof. Haitham Amal. NeuroNOS has secured FDA Orphan Drug Designations for Phelan-McDermid Syndrome and Glioblastoma. XTL will pay 19.9% of its share capital, $1 million cash, and up to $32.5 million in milestone payments.Benzinga · Jan 13, 2026

Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross ProceedsBeyond Air will exercise existing warrants to purchase 1,439,126 shares at $2.21 per share, generating approximately $3.25 million in gross proceeds. The company will simultaneously issue new unregistered warrants and plans to use the funds for clinical programs and operating expenses.GlobeNewswire Inc. · Sep 8, 2025

Beyond Air Signs New International LungFit PH® Distribution Agreements, Most Notably in JapanBeyond Air has signed new distribution agreements in Japan, South Korea, Costa Rica, Guatemala, Panama, and El Salvador, expanding its international LungFit PH network to 34 countries representing 2.7 billion people.GlobeNewswire Inc. · Aug 20, 2025

to start trading

XA

XAIRBeyond Air, Inc. Common Stock

XAIR

Pay with—

Available Balance0.00

Your PositionYou don't own any XAIR yet.

Related Tickers

Earnings